<DOC>
	<DOCNO>NCT02222545</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , clinical activity OMS721 subject thrombotic microangiopathies ( TMA ) , include atypical hemolytic uremic syndrome ( aHUS ) , thrombotic thrombocytopenia ( TTP ) , hematopoietic stem cell transplant -associated TMA ( HSCT-associated TMA ) . The study also evaluate clinical activity , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , anti-drug antibody response ( ADA ) .</brief_summary>
	<brief_title>Safety Efficacy Study OMS721 Patients With Thrombotic Microangiopathies</brief_title>
	<detailed_description>This Phase 2 , uncontrolled , three-stage , dose-escalation cohort study subject three form TMA : atypical hemolytic uremic syndrome ( aHUS ) , thrombotic thrombocytopenia ( TTP ) , hematopoietic stem cell transplant -associated TMA ( HSCT-associated TMA ) . In first stage , OMS721 administer escalate dose cohort three subject per cohort identify optimal dose regimen . In second stage , dose select first stage administer expand cohort 40 subject per cohort distinct etiology ( aHUS alone one cohort TTP HSCT-TMA cohort ) . Subjects complete second stage may eligible continued treatment third stage investigator believe subject risk relapse TMA , subject tolerate OMS721 treatment , subject condition increase risk OMS721 treatment .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Thrombotic Microangiopathies</mesh_term>
	<criteria>1 . Are least age 18 screening ( Visit 1 ) 2 . Have diagnosis primary aHUS , persistent HSCTassociated TMA TTP 3 . No clinically apparent alternative explanation thrombocytopenia anemia 1 . Had eculizumab therapy within three month prior screen 2 . Have STECHUS 3 . Have positive direct Coombs test 4 . Have active systemic bacterial fungal infection require antimicrobial therapy ( prophylactic antimicrobial therapy administer standard care allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>TMA , aHUS , HSCT-associated TMA , TTP</keyword>
</DOC>